{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"}]}],"title":"TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"7"}]}],"title":"Treatment-related (TR) TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"}]}],"title":"Grade 3 or 4 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"7"}]}],"title":"TR Grade 3 or 4 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"}]}],"title":"Serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"}]}],"title":"TR Serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}],"title":"TEAE Leading to Drug Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}],"title":"TR TEAE Leading to Drug Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]}],"title":"TEAE Leading to Dose Reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]}],"title":"TR TEAE Leading to Dose Reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]}],"title":"TEAE Leading to Drug Interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]}],"title":"TR TEAE Leading to Drug Interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}],"title":"TEAE Leading to Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"TR TEAE Leading to Death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"description":"An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE (SAE) is any AE occurring at any dose that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAEs were defined as AEs that began or worsened in severity on or after the date of the first dose of study drug and within 28 days of the date of the last dose of study drug. The severity of an AE was graded according to the CTCAE, Version 4.0.","groups":[{"description":"nab-paclitaxel 120 mg/m\\^2 intravenously (IV) on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the recommended phase 2 dose (RP2D).","id":"OG000","title":"Phase 1: Nab-Paclitaxel 120 mg/m^2"},{"description":"nab-paclitaxel 150 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG001","title":"Phase 1: Nab-Paclitaxel 150 mg/m^2"},{"description":"nab-paclitaxel 180 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG002","title":"Phase 1: Nab-Paclitaxel 180 mg/m^2"},{"description":"nab-paclitaxel 210 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG003","title":"Phase 1: Nab-Paclitaxel 210 mg/m^2"},{"description":"nab-paclitaxel 240 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG004","title":"Phase 1: Nab-Paclitaxel 240 mg/m^2"},{"description":"nab-paclitaxel 270 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG005","title":"Phase 1: Nab-Paclitaxel 270 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population: all participants who took at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Median treatment duration in Phase 1 was 7.0 weeks, with minimum and maximum duration of 1 and 49 weeks, respectively. Participants were followed for 28 days after discontinuing treatment for safety and monitoring of AEs.","title":"Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","type":"PRIMARY","unitOfMeasure":"Participants"}